Breast Cancer Microvesicles as a Novel Plasma Biomarker and Therapeutic Target (IDEA)
Annual rept. 30 Mar 2007-29 Mar 2008
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
We have developed a bead capture assay for quantitation of breast cancer tumor microvesicles MV to predict clinical outcomes in breast cancer patients. Flow cytometry as originally proposed and as used by numerous investigators is inadequate for this task. Anti-MUCI coated beads are used to bind and isolate tumor MV from patient plasma. We have introduced a 100 nm filtration step of plasma prior to bead-capture in order to eliminate the contribution of soluble antigens and smaller exosomes. This allows to specifically assay MV of epithelial origin in the blood. We have adapted this platform to assay MUCI MV for total protein tissue factor MMP-9 and total DNA. We have banked over 200 clinical samples are beginning to use these assays to begin to determine if breast cancer MV may represent a biomarker associated with more aggressive disease and a potential therapeutic target.
- Medicine and Medical Research